Navigation Links
Revisiting the anthrax attacks

PITTSBURGH, Jan. 22 When anthrax was sent through the U.S. Postal Service in 2001, an overwhelming majority of postal workers elected not to be inoculated with the available vaccine because of confusion and distrust, according to a University of Pittsburgh Graduate School of Public Health study. Although the FBI officially closed the case on the attacks this year, lingering suspicion and uncertainty remain, say study authors, which could influence the public's reactions to future emergencies.

According to the report, reactions from postal workers were shaped partially by fears of being experimental "guinea pigs," disagreements among public health agencies about whether the vaccine should be recommended, physician advice, low perceived risk of infection and conflicting reports from national media organizations.

The study was based on interviews and focus groups conducted with 65 postal workers in Trenton, N.J., New York and Washington, and published in the December 2008 issue of Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science.

"The reaction of postal workers demonstrates the essential need to build trust and educate the public before the uncertainty, confusion and time pressures of a bioterrorism or pandemic emergency create major barriers for clear communication," said study author, Sandra Quinn, Ph.D., associate dean for Student Affairs and Education and associate professor at the University of Pittsburgh's Graduate School of Public Health. These concerns may be particularly relevant given that, in October 2008, the Department of Health and Human Services declared anthrax as a continuing bioterrorism threat through the end of 2015, she said.

During the 2001 anthrax attacks, which resulted in five deaths, 10,000 postal workers and others who were suspected or confirmed to have been exposed received a two-month dose of antibiotics. The Centers for Disease Control and Prevention (CDC) then recommended people who failed to complete the regimen or who were at high risk for exposure take antibiotics for an additional 40 days with or without a supplemental anthrax vaccine. Only 11.5 percent of postal workers who took the additional 40-day dose of antibiotics agreed to take the anthrax vaccine as a precautionary measure.

"Scientific knowledge about the effectiveness of the vaccine after exposure to anthrax was uncertain at the time, making it an almost impossible task to communicate precise and proper health information to postal workers and other affected groups, including Senate staff," said Dr. Quinn. "Given the evolving nature of the crisis, postal workers were unsure whose advice they should trust and as a result, many decided to do without the recommended vaccination," she said.

In 2004, with the passage of legislation to establish Project Bioshield, the federal government created a mechanism for declaring public health emergencies. This authority also allows the Food and Drug Administration to authorize the use of experimental or "off label" drugs to address bioterrorism or public health emergencies. According to Dr. Quinn, communication about the use of these counter measures will present significant challenges for public health authorities in the future.

To address these challenges, she suggests public health experts openly acknowledge disagreements between health agencies, develop partnerships with trusted community agencies and work with media partners to address inaccuracies, misconceptions or other issues that may arise in news reports.

"We need to engage and educate the public before an emergency occurs to prevent unnecessary risk, disease and even death. Only by doing this can individuals make informed decisions about accepting or rejecting counter measures," she said.


Contact: Clare Collins
University of Pittsburgh Schools of the Health Sciences

Related medicine news :

1. Nasal Anthrax Vaccine Proves Effective in Animal Study
2. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
3. Key Anthrax Virulence Factor Discovered
4. Is a cup of tea really the answer to everything -- even anthrax?
5. Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine
6. Researchers Pursuing Nasal Anthrax Vaccine
7. Heart Attacks at School Involve More Adults Than Kids
8. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
9. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
10. Treating obstructive sleep apnea, preventing heart attacks and strokes
11. Panic Attacks May Hike Heart Disease Risk in Women
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to share their knowledge and experiences at a live taping of the next ... Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel ...
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... ... Shoulder , LLC launched their Pro Vest, the latest version of their widely popular weight ... under 10 hours. , The campaign, which will continue to run through ... market. , The PRO Vest provides consumers with a less expensive, one-size fits all comfort ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- Teledyne DALSA , a Teledyne Technologies company and ... its CMOS X-Ray detector for mammography at the ... 3, at McCormick Place in Chicago . ... imaging will be on display in the South Hall, Booth ... X-Ray detectors is the industry benchmark for high speed imaging ...
(Date:11/24/2015)... 24, 2015 The uptake of recently approved and ... key driver of market growth to 2021, says GBI ... pipeline premium products for Type 1 Diabetes Mellitus (T1DM), will be a ... Research . --> The uptake of recently approved ... a key driver of market growth to 2021, says ...
(Date:11/24/2015)... NEWTOWN, Pa. , Nov. 24, 2015  NuShield, Inc., an industry leader in LCD screen ... mobile and stationary computer technology as part of their patient monitoring or electronic documentation system. ... ... ... ...
Breaking Medicine Technology: